Traditional Resistance to EGFR Inhibitors May Not Effect Responses With Amivantamab/Lazertinib in EGFR+ NSCLC
More than a third of patients who progressed on osimertinib (Tagrisso) therapy for EGFR-positive non–small cell lung cancer (NSCLC) had a response to the combination of amivantamab (Rybervant) plus lazertinib, according to results of a cohort of the CHRYSALIS trial (NCT02609776) presented during the 2021 ASCO Annual Meeting. Biomarker analysis in the cohort also helped to identify patients that may be more likely to respond to the combination, which may not be based solely on the underlying genetic mechanisms of resistance, presenter Byoung Chul Cho, MD, PhD, suggested. Amivantamab is a fully human bi-specific antibody targeting EGFR and MET that recently received FDA approval for the frontline treatment of adult patients with EGFR exon 20 insertion–mutant NSCLC. Lazertinib is a potent third-generation EGFR tyrosine kinase inhibitor (TKI) that shows a promising safety profile, including low rates of EGFR-related toxicities.